Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1249

1.

Shared decision making in preventive care in Switzerland: From theory to action.

Selby K, Auer R, Cornuz J.

Z Evid Fortbild Qual Gesundhwes. 2017 May 17. pii: S1865-9217(17)30083-1. doi: 10.1016/j.zefq.2017.05.008. [Epub ahead of print]

PMID:
28527635
2.

The context of prostate cancer genomics in personalized medicine.

Liu Y.

Oncol Lett. 2017 May;13(5):3347-3353. doi: 10.3892/ol.2017.5911. Epub 2017 Mar 24.

3.

Association between features of patient-provider discussions and routine prostate-specific antigen testing.

Liao JM, Ommerborn MJ, Clark CR.

PLoS One. 2017 May 16;12(5):e0177687. doi: 10.1371/journal.pone.0177687. eCollection 2017.

4.

Active Surveillance for Prostate Cancer: How to Do It Right.

Garisto JD, Klotz L.

Oncology (Williston Park). 2017 May 15;31(5):333-40, 345. Review.

5.

Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.

Hoffman RM, Lo M, Clark JA, Albertsen PC, Barry MJ, Goodman M, Penson DF, Stanford JL, Stroup AM, Hamilton AS.

J Clin Oncol. 2017 May 11:JCO2016706317. doi: 10.1200/JCO.2016.70.6317. [Epub ahead of print]

PMID:
28493812
6.

Factors influencing the decision to attend screening for cancer in the UK: a meta-ethnography of qualitative research.

Young B, Bedford L, Kendrick D, Vedhara K, Robertson JFR, das Nair R.

J Public Health (Oxf). 2017 May 9:1-25. doi: 10.1093/pubmed/fdx026. [Epub ahead of print]

PMID:
28486650
7.

Harnessing Information Technology to Inform Patients Facing Routine Decisions: Cancer Screening as a Test Case.

Krist AH, Woolf SH, Hochheimer C, Sabo RT, Kashiri P, Jones RM, Lafata JE, Etz RS, Tu SP.

Ann Fam Med. 2017 May;15(3):217-224. doi: 10.1370/afm.2063.

9.

Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort.

Eure G, Germany R, Given R, Lu R, Shindel AW, Rothney M, Glowacki R, Henderson J, Richardson T, Goldfischer E, Febbo PG, Denes B.

Urology. 2017 Apr 25. pii: S0090-4295(17)30374-6. doi: 10.1016/j.urology.2017.02.052. [Epub ahead of print]

10.

Multiparametric MRI Apparent Diffusion Coefficient (ADC) Accuracy in Diagnosing Clinically Significant Prostate Cancer.

Pepe P, D'Urso D, Garufi A, Priolo G, Pennisi M, Russo G, Sabini MG, Valastro LM, Galia A, Fraggetta F.

In Vivo. 2017 May-Jun;31(3):415-418.

PMID:
28438871
11.

The Effect of Cancer Patients' and Their Family Caregivers' Physical and Emotional Symptoms on Caregiver Burden.

Johansen S, Cvancarova M, Ruland C.

Cancer Nurs. 2017 Apr 20. doi: 10.1097/NCC.0000000000000493. [Epub ahead of print]

PMID:
28426539
12.

Decision aids for people facing health treatment or screening decisions.

Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L.

Cochrane Database Syst Rev. 2017 Apr 12;4:CD001431. doi: 10.1002/14651858.CD001431.pub5. Review.

PMID:
28402085
13.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30267-1. doi: 10.1016/j.eururo.2017.03.039. [Epub ahead of print]

PMID:
28400169
14.

A Survey of the Knowledge of African-American Women About Prostate Cancer Screening.

Eastland TY.

J Cancer Educ. 2017 Apr 8. doi: 10.1007/s13187-017-1220-9. [Epub ahead of print]

PMID:
28391558
15.

Persuasive Interventions for Controversial Cancer Screening Recommendations: Testing a Novel Approach to Help Patients Make Evidence-Based Decisions.

Saver BG, Mazor KM, Luckmann R, Cutrona SL, Hayes M, Gorodetsky T, Esparza N, Bacigalupe G.

Ann Fam Med. 2017 Jan;15(1):48-55. doi: 10.1370/afm.1996. Epub 2017 Jan 6.

16.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

Pinsky PF, Prorok PC, Kramer BS.

N Engl J Med. 2017 Mar 30;376(13):1285-1289. doi: 10.1056/NEJMsb1616281. No abstract available.

PMID:
28355509
17.

Novel biomarkers for the detection of prostate cancer.

Jakobsen NA, Hamdy FC, Bryant RJ.

J Clin Urol. 2016 Dec;9(2 Suppl):3-10. doi: 10.1177/2051415816656121. Epub 2016 Dec 1.

18.

How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer.

Lamers RE, Cuypers M, de Vries M, van de Poll-Franse LV, Ruud Bosch JL, Kil PJ.

Urol Oncol. 2017 Feb;35(2):37.e9-37.e17. doi: 10.1016/j.urolonc.2016.09.007. Epub 2016 Oct 27.

PMID:
28341494
19.

An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.

Raymond E, O'Callaghan ME, Campbell J, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti K.

Radiat Oncol. 2017 Mar 21;12(1):56. doi: 10.1186/s13014-017-0786-z.

20.

Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.

Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF.

JAMA. 2017 Mar 21;317(11):1126-1140. doi: 10.1001/jama.2017.1704.

PMID:
28324093

Supplemental Content

Loading ...
Support Center